IVF — INVO Fertility, Inc.

INVO Fertility, Inc. (IVF) is a medical devices company listed on NASDAQ. It is led by Steven M. Shum, based in 5582 Broadcast Court, Sarasota, FL, United States, 34240, with about 33 employees. INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services; INVOcell Device; and Therapeutics segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. It also operates fertility clinics, including INVO Centers. In addition, the company develops NY-303, a GPC3 x NKp46 bifunctional antibody that is in Phase i/ii a monotherapy trial for the treatment of hepatocellular carcinoma; and NY-500, an AI-optimized bifunctional antibody. The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025. INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.

Latest reported IVF revenue for 2026-06-30 was $2.2M. Net income was $888.7K. Revenue was up 8.0% from 2026-03-31 to 2026-06-30. IVF currently screens at market cap $2.8M.

Use this IVF page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IVF quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IVF SEC filings page. Lician reads the product cache first so this HTML stays unique to INVO Fertility, Inc. even when a live quote feed is slow.